Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

teva b.v., haarlem array - 16097 posakonazol - enterosolventní tableta - 100mg - posakonazol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 16097 posakonazol - enterosolventní tableta - 100mg - posakonazol

Evropská unie - čeština - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - neoplazmy žaludku - antineoplastická činidla - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Evropská unie - čeština - EMA (European Medicines Agency)

octapharma ab - simoctocog alfa - hemofilie a - faktory koagulace krve - léčba a profylaxe krvácení u pacientů s hemofilií a (vrozený nedostatek faktoru viii). nuwiq může být použit pro všechny věkové skupiny.

Evropská unie - čeština - EMA (European Medicines Agency)

instituto grifols s.a. - normální lidský imunoglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - imunitní séra a imunoglobuliny, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Evropská unie - čeština - EMA (European Medicines Agency)

astrazeneca ab - olaparib - ovariální nádory - antineoplastická činidla - ovariální cancerlynparza je indikován jako monoterapie pro:udržovací léčbě dospělých pacientů s pokročilým (figo stadia iii a iv) brca1/2-mutované (germline a/nebo somatickou) high-grade epiteliální vaječníků, vejcovodů nebo primární peritoneální rakovinou, kteří jsou v odpovědi (úplné nebo částečné) po ukončení první linie chemoterapie na bázi platiny. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 a 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacienti by byli dříve léčeni antracyklin a taxan v (neo)adjuvantní nebo metastatického onemocnění, s výjimkou pacientů, nejsou vhodné pro tyto léčby (viz bod 5. pacienti s hormonální receptory (hr)-pozitivním karcinomem prsu by měly mít také postupoval na nebo po předchozí endokrinní léčbě nebo být považovány za nevhodné pro endokrinní terapii. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Evropská unie - čeština - EMA (European Medicines Agency)

octapharma ab - simoctocog alfa - hemofilie a - antihemoragika - léčba a profylaxe krvácení u pacientů s hemofilií a (vrozený nedostatek faktoru viii). vihuma může být použit pro všechny věkové skupiny.

Evropská unie - čeština - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemoragická horečka, horečka ebola - vakcíny - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

linde sverige ab, solna array - 2473 oxid dusnÝ; 3084 kyslÍk - medicinální plyn, stlačený - 50%/50% - oxid dusnÝ, kombinace

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi ab, uppsala array - 4957 monohydrÁt glukosy; 1354 ČiŠtĚnÝ sÓjovÝ olej; 27 alanin; 96 arginin; 103 kyselina asparagovÁ; 665 kyselina glutamovÁ; 55 glycin; 717 histidin; 790 isoleucin; 829 leucin; 851 lysin-hydrochlorid; 2445 methionin; 1117 fenylalanin; 4147 prolin; 4717 serin; 1459 threonin; 1503 tryptofan; 1507 tyrosin; 1514 valin; 5599 dihydrÁt chloridu vÁpenatÉho; 16396 natrium-glycerofosfÁt; 864 heptahydrÁt sÍranu hoŘeČnatÉho; 1174 chlorid draselnÝ; 1306 trihydrÁt natrium-acetÁtu - infuzní emulze - roztoky pro parenterÁlnÍ vÝŽivu, kombinace